{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:55:27Z","timestamp":1762102527657,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002973","name":"DaiichiSankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shino-Test Corporation"},{"DOI":"10.13039\/100009015","name":"Abbott Japan Co., Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009015","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Initiative for Global Research Network on Infectious Diseases"},{"DOI":"10.13039\/501100001700","name":"the Ministry of Education, Culture, Sport, Science & Technology in Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ak0101118h0001"],"award-info":[{"award-number":["JP19ak0101118h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005946","name":"Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005946","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000646","name":"JSPS KAKENHI","doi-asserted-by":"publisher","award":["JP19K18566","JP19K16648","19K18566"],"award-info":[{"award-number":["JP19K18566","JP19K16648","19K18566"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jiac.2020.07.009","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T01:19:30Z","timestamp":1596590370000},"page":"1272-1277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sitafloxacin has a potent activity for eradication of extended spectrum \u03b2-lactamase-producing fluoroquinolone-resistant Escherichia coli forming intracellular bacterial communities in uroepithelial cells"],"prefix":"10.1016","volume":"26","author":[{"given":"Yoshiki","family":"Hiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyotaka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soh","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Masumori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jiac.2020.07.009_bib1","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1093\/cid\/ciy1121","article-title":"Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the infectious Diseases society of America","volume":"68","author":"Nicolle","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2020.07.009_bib2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1542\/peds.64.4.433","article-title":"Asymptomatic bacteriuria in adolescent girls: I. Epidemiology","volume":"64","author":"Emans","year":"1979","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.jiac.2020.07.009_bib3","first-page":"367","article-title":"Asymptomatic bacteriuria: when to screen and when to treat","volume":"17","author":"Nicolle","year":"2003","journal-title":"Infect Dis Clin"},{"issue":"3","key":"10.1016\/j.jiac.2020.07.009_bib4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cger.2016.03.002","article-title":"Urinary tract infections in the older adult","volume":"32","author":"Nicolle","year":"2016","journal-title":"Clin Geriatr Med"},{"issue":"6","key":"10.1016\/j.jiac.2020.07.009_bib5","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/infdis\/146.6.719","article-title":"A\u00a0prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters","volume":"146","author":"Warren","year":"1982","journal-title":"J\u00a0Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2020.07.009_bib6","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/cid\/civ696","article-title":"Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections","volume":"61","author":"Cai","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2020.07.009_bib7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2017.07.014","article-title":"Benefits and harms of treatment of asymptomatic bacteriuria: a systematic review and meta-analysis by the European association of urology urological infection guidelines panel","volume":"72","author":"K\u00f6ves","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.jiac.2020.07.009_bib8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s10156-009-0721-9","article-title":"Efficacy of treatment with carbapenems and third-generation cephalosporins for patients with febrile complicated pyelonephritis","volume":"15","author":"Takahashi","year":"2009","journal-title":"J\u00a0Infect Chemother"},{"issue":"7","key":"10.1016\/j.jiac.2020.07.009_bib9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jiac.2016.04.004","article-title":"Clinical analysis of bacterial strain profiles isolated from urinary tract infections: a 30-year study","volume":"22","author":"Wada","year":"2016","journal-title":"J\u00a0Infect Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2020.07.009_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220265","article-title":"The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017","volume":"14","author":"Critchley","year":"2019","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.jiac.2020.07.009_bib11","doi-asserted-by":"crossref","first-page":"E356","DOI":"10.3390\/medicina55070356","article-title":"Comparative epidemiology and resistance trends of common urinary pathogens in a tertiary-care hospital: a 10-year surveillance study","volume":"55","author":"Gajd\u00e1cs","year":"2019","journal-title":"Medicina"},{"issue":"5","key":"10.1016\/j.jiac.2020.07.009_bib12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.49.5.2137-2139.2005","article-title":"High levels of antimicrobial coresistance among extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"49","author":"Schwaber","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jiac.2020.07.009_bib13","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1128\/AAC.00155-06","article-title":"Antibiotic coresistance in extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline","volume":"50","author":"Morosini","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jiac.2020.07.009_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000361011","article-title":"High prevalence of cross-resistance to aminoglycosides in fluoroquinolone-resistant Escherichia coli clinical isolates","volume":"59","author":"Tsukamoto","year":"2013","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.jiac.2020.07.009_bib15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.jiac.2020.07.009_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14787210.6.5.671","article-title":"Clinical significance of extended-spectrum \u03b2-lactamases","volume":"6","author":"Rodr\u00edguez-Ba\u00f1o","year":"2008","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"10.1016\/j.jiac.2020.07.009_bib17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"14","key":"10.1016\/j.jiac.2020.07.009_bib18","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1128\/jb.177.14.4194-4197.1995","article-title":"MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli","volume":"177","author":"Brown","year":"1995","journal-title":"J\u00a0Bacteriol"},{"issue":"sup1","key":"10.1016\/j.jiac.2020.07.009_bib19","first-page":"2","article-title":"Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review","volume":"29","author":"Mazzariol","year":"2017","journal-title":"J\u00a0Chemother"},{"year":"2018","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","key":"10.1016\/j.jiac.2020.07.009_bib20"},{"year":"2020","series-title":"Performance Standards for antimicrobial susceptibility testing","key":"10.1016\/j.jiac.2020.07.009_bib21"},{"issue":"4","key":"10.1016\/j.jiac.2020.07.009_bib22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.12938\/bmfh.16-003","article-title":"DFAST and DAGA: web-based integrated genome annotation tools and resources","volume":"35","author":"Tanizawa","year":"2016","journal-title":"Biosci Microbiota Food Health"},{"issue":"11","key":"10.1016\/j.jiac.2020.07.009_bib23","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1093\/jac\/dks261","article-title":"Identification of acquired antimicrobial resistance genes","volume":"67","author":"Zankari","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2020.07.009_bib24","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1073\/pnas.120163297","article-title":"One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products","volume":"97","author":"Datsenko","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jiac.2020.07.009_bib25","doi-asserted-by":"crossref","first-page":"ftz022","DOI":"10.1093\/femspd\/ftz022","article-title":"Fosfomycin tromethamine activity on biofilm and intracellular bacterial communities produced by uropathogenic Escherichia coli isolated from patients with urinary tract infection","volume":"77","author":"Gonz\u00e1lez","year":"2019","journal-title":"Pathog Dis"},{"issue":"5","key":"10.1016\/j.jiac.2020.07.009_bib26","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1128\/AAC.00014-10","article-title":"Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics","volume":"54","author":"Blango","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2020.07.009_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1128\/AAC.39.1.170","article-title":"Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers","volume":"39","author":"Nakashima","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1016\/j.jiac.2020.07.009_bib28","first-page":"258","article-title":"Clinical Phase I study of meropenem","volume":"40","author":"Nakashima","year":"1992","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2020.07.009_bib29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jiac.2020.07.009_bib30","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1128\/AAC.05104-11","article-title":"Dissemination of the fosfomycin resistance gene fosA3 with CTX-M \u03b2-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China","volume":"56","author":"Hou","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jiac.2020.07.009_bib31","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1093\/jac\/dks319","article-title":"Prevalence of acquired fosfomycin resistance among extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3","volume":"67","author":"Lee","year":"2012","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.jiac.2020.07.009_bib32","article-title":"Antimicrobial susceptibility and molecular mechanisms of fosfomycin resistance in clinical Escherichia coli isolates in mainland China","volume":"10","author":"Li","year":"2015","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.jiac.2020.07.009_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135864","article-title":"Characterization of fosfomycin resistant extended-spectrum \u03b2-lactamase-producing Escherichia coli isolates from human and pig in taiwan","volume":"10","author":"Tseng","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.jiac.2020.07.009_bib34","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1086\/427507","article-title":"Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults.","volume":"40","author":"Nicolle","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2020.07.009_bib35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"JAID\/JSC guidelines for clinical management of infectious disease 2015 - urinary tract infection\/male genital infection","volume":"23","author":"Japanese Association for Infectious Disease\/Japanese Society of Chemotherapy","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2020.07.009_bib36","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1038\/s41467-019-11571-5","article-title":"Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection","volume":"10","author":"Forde","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jiac.2020.07.009_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/jac\/dkm464","article-title":"Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15","volume":"61","author":"Nicolas-Chanoine","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jiac.2020.07.009_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3201\/eid1402.070350","article-title":"Dissemination of clonally related Escherichia coli strains expressing extended-spectrum \u03b2-lactamase CTX-M-15","volume":"14","author":"Coque","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.009_bib39","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.2147\/IDR.S212658","article-title":"Escherichia coli O25b-ST131 and O16-ST131 causing urinary tract infection in women in Changsha, China: molecular epidemiology and clinical characteristics","volume":"12","author":"Zhong","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiac.2020.07.009_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.aambs.2014.09.002","article-title":"Escherichia coli ST131: the quintessential example of an international multiresistant high-risk clone","volume":"90","author":"Mathers","year":"2015","journal-title":"Adv Appl Microbiol"},{"issue":"1","key":"10.1016\/j.jiac.2020.07.009_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.UTI-0013-2012","article-title":"Drug and vaccine development for the treatment and prevention of urinary tract infections","volume":"4","author":"O\u2019Brien","year":"2016","journal-title":"Microbiol Spectr"},{"issue":"6","key":"10.1016\/j.jiac.2020.07.009_bib42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/infdis\/jit245","article-title":"A\u00a0FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131","volume":"208","author":"Totsika","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.009_bib43","doi-asserted-by":"crossref","first-page":"16149","DOI":"10.1038\/srep16149","article-title":"The role of H4 flagella in Escherichia coli ST131 virulence","volume":"5","author":"Kakkanat","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2020.07.009_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1099\/mic.0.052043-0","article-title":"Nicotinamide dependence of uropathogenic Escherichia coli UTI89 and application of nadB as a neutral insertion site","volume":"158","author":"Li","year":"2012","journal-title":"Microbiology"},{"key":"10.1016\/j.jiac.2020.07.009_bib45","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.02552-13","article-title":"Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens","volume":"58","author":"Goneau","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiac.2020.07.009_bib46","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/jac\/dki059","article-title":"Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages","volume":"55","author":"Seral","year":"2005","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.jiac.2020.07.009_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jac\/44.2.193","article-title":"Intracellular activity of trovafloxacin against Staphylococcus aureus","volume":"44","author":"van den Broek","year":"1999","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2020.07.009_bib48","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.3390\/antibiotics6040024","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics"},{"issue":"8","key":"10.1016\/j.jiac.2020.07.009_bib49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jiac.2017.05.005","article-title":"A\u00a0randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli: a pilot study","volume":"23","author":"Malaisri","year":"2017","journal-title":"J\u00a0Infect Chemother"},{"issue":"1","key":"10.1016\/j.jiac.2020.07.009_bib50","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000336129","article-title":"Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan","volume":"58","author":"Yokota","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jiac.2020.07.009_bib51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2020.07.009_bib52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijid.2012.09.010","article-title":"The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"17","author":"Doi","year":"2013","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20302221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20302221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:00:42Z","timestamp":1761159642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X20302221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1341321X20302221"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2020.07.009","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sitafloxacin has a potent activity for eradication of extended spectrum \u03b2-lactamase-producing fluoroquinolone-resistant Escherichia coli forming intracellular bacterial communities in uroepithelial cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2020.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}